ChristopherPSullivanMD

Endocrinology • Akron, OH

Diabetes, Lipid Metabolism

Physician

Join to view full profile

Are you Dr. Sullivan?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 54 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
75 Arch St
Suite 301
Akron, OH 44304
Phone+1 330-253-1899

Fax+1 330-253-2108
Is this information wrong?

Summary

Dr. Christopher Sullivan, MD is an endocrinologist in Akron, Ohio. He is currently licensed to practice medicine in Ohio. He is affiliated with Summa Health System – Akron Campus.

Education & Training

Cleveland Clinic FoundationFellowship, Endocrinology, Diabetes, and Metabolism, 1987 - 1989
Summa Health System/NEOMEDResidency, Internal Medicine, 1985 - 1987
Summa Health System/NEOMEDResidency, Internal Medicine, 1981 - 1981
Summa Health System/NEOMEDResidency, Internal Medicine, 1980 - 1980
Ohio State University College of MedicineClass of 1979

Certifications & Licensure

OH State Medical License 1980 - 2022

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2011
Diabetes Recognition Program National Committee for Quality Assurance, 2010-2013

Publications & Presentations

PubMed

Trafficking of endogenous smooth muscle cell cholesterol: a role for serum amyloid A and interleukin-1β.
Pessolano LG, Sullivan CP, Seidl SE, Rich CB, Liscum L, Stone PJ, Sipe JD, Schreiber BM> ;Arterioscler. Thromb. Vasc. Biol.. 2012-11-01
32 citations
Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.
Christopher P. Sullivan, Eric A. Berg, Rosemary Elliott-Bryant, Jordan B. Fishman, Ann C. McKee, Peter J. Morin, Michael A. Shia, Richard E. Fine> ;Neuroscience Letters. 2011 Nov 14
77 citations
RETROMER DISRUPTION PROMOTES AMYLOIDOGENIC APP PROCESSING
Christopher P. Sullivan, Anthony G. Jay, Edward C. Stack, Maria Pakaluk, Erin Wadlinger, Richard E. Fine, John M. Wells, Peter J. Morin> ;Neurobiology of Disease. 2011 Aug 1
Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mech...
Sullivan, C.P., Seidl, S.E., Rich, C.B., Raymondjean, M., Schreiber, B.M.> ;J Biol Chem. 2010-01-01
B-Myb represses elastin gene expression in aortic smooth muscle cells.
Hofmann, C.S., Wang, X., Sullivan, C.P., Toselli, P., Stone, P.J., McLean, S.E., Mecham, R.P., Schreiber, B.M., Sonenshein, G.E.> ;J Biol Chem. 2005 Mar 4
B-Myb represses vascular smooth muscle cell collagen gene expression and inhibits neointima formation after arterial injury.
Hofmann, C.S., Sullivan, C.P., Jiang, H., Stone, P.J., Toselli, P., Reis, E.D., Chereshnev, I., Schreiber, B.M., Sonenshein, G.E.> ;Arterioscler Thromb Vasc Biol. 2004 Sep
26 citations
A3 adenosine receptor deficiency does not influence atherogenesis
Matthew R. Jones, Zhihui Zhao, Christopher P. Sullivan, Barbara M. Schreiber, Phillip J. Stone, Paul Toselli, H. Kagan, Richard A. Cohen, Katya Ravid> ;Journal of Cellular Biochemistry. 2004 Aug 1
Identification of a cytokine-induced repressor of interleukin-1 stimulated expression of stromelysin 1 (MMP-3).
Borghaei RC, Sullivan C, Mochan E> ;J. Biol. Chem.. 1999-01-22
Join now to see all

Hospital Affiliations

Summa Health System – Akron CampusAkron, Ohio